Abstract 2531: Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Diabetes Mellitus: Patient-Level Meta-Analysis of Randomized Trials

Although it is widely believed that patients with diabetes mellitus obtain the greatest benefit from sirolimus-eluting stent, the evidence on the efficacy and safety of stents of this nature is limited. We performed a meta-analysis based on individual patient data from 4 randomized trials (586 patients) comparing sirolimus-eluting with bare metal stents (mean follow-up interval between 12 and 24 months). The primary efficacy endpoint was the need of reintervention. The primary safety endpoint was all-cause mortality. Myocardial infarction and stent thrombosis rates were also evaluated. There was a significant reduction in the overall hazard of repeat revascularization (HR 0.21, 95% confidence interval [CI] 0.13 to 0.33, P